Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketoconazole + zinc pyrithione is a topical combination therapy developed by Biogracea Medicare for the treatment of fungal skin infections and scalp conditions such as seborrheic dermatitis and dandruff. Ketoconazole, an imidazole derivative, exerts its antifungal effect by inhibiting the enzyme lanosterol 14-alpha demethylase, which is critical for the biosynthesis of ergosterol in fungal cell membranes. Zinc pyrithione is a coordination complex that possesses both antifungal and antibacterial properties; it is thought to work by disrupting membrane transport and cellular metabolism, potentially through the regulation of intracellular metal ion concentrations. This synergistic combination is typically delivered in a shampoo or lotion base, providing both rapid symptomatic relief and long-term control of Malassezia-related conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketoconazole + zinc pyrithione.